Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study

Diabetes Care. 2008 Mar;31(3):445-7. doi: 10.2337/dc07-0196. Epub 2007 Dec 10.

Abstract

Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between LDL cholesterol levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebo-based antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.

Trial registration: ClinicalTrials.gov NCT00308347.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albuminuria / metabolism
  • Cholesterol, LDL / analysis*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / metabolism
  • Humans
  • Kidney Failure, Chronic / chemically induced*
  • Kidney Failure, Chronic / metabolism
  • Losartan / adverse effects*
  • Losartan / therapeutic use
  • Randomized Controlled Trials as Topic

Substances

  • Cholesterol, LDL
  • Losartan

Associated data

  • ClinicalTrials.gov/NCT00308347